
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow is well-positioned for future growth in the biopharmaceutical industry, with a strong pipeline of products and partnerships focusing on the growing demand for eye care treatments. Despite reimbursement challenges, the company's strong management team and successful revenue growth make it a promising investment opportunity in the long term.
Bears say
Harrow is facing numerous headwinds in the eyecare pharmaceutical market due to its crowded dry-eye market, limited exclusivity for its products, and potential biosimilar competition in the future. Despite its current strong portfolio, their growth potential is not reflected in their current multiple and their immediate growth prospects are lower than market expectations, making their stock a risky investment.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares